The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, on behalf of the Centers for Disease Control and Prevention, Department of Health and Human Services, is contemplating the grant of an exclusive patent commercialization license to The University of Liverpool, located in Liverpool, UK, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
Document
Prospective Grant of Exclusive Patent Commercialization License: Streptococcus Pneumonia PSAA Peptide for Treatment of Sepsis and Infection
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, on behalf of the Centers f...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 28002
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Exclusive Patent Commercialization License: Streptococcus Pneumonia PSAA Peptide for Treatment of Sepsis and Infection,” thefederalregister.org (June 15, 2018), https://thefederalregister.org/documents/2018-12838/prospective-grant-of-exclusive-patent-commercialization-license-streptococcus-pneumonia-psaa-peptide-for-treatment-of-se.